MARATTO

article · International Journal of Immunology

Immunohistopathological Profile and Biomolecular Level of Central Nerve Tumors in Kinshasa, DRC According to the Classification of the World Health Organization 2016

Abstract

The goal is to determine immunohistochemical histopathological profile and biomolecular level of Central nerve Tumors in Kinshasa, DRC. According to the classification of the World Health Organization (WHO) 2016. Our study is described on a series of cases that were studied using standard histopathological techniques, before undergoing specific immunohistochemical techniques for the detection of anti-IDH1antibodies in gliomas and biomolecular ones in the search for 1p19q deletion. Central nerve tumors account for 0.18% of all conditions, over a period of time. Meningothelial-type meningioma was the most common (60.9%). The most affected age group is over 50. The distribution of tumors by sex shows a predominance of woman (67.1%). The gliomas had constituted 29.6% of all nerve tumors recorded over the period considered and whose predominance was constituted by oligoastrocytomas with 42.1%. The immunohistochemical profile is characterized by a strong positivity with the anti-IDH1antibody in case of grade II oligoastrocytoma with 6.6%. Our study showed that central nerve tumors account for 0.18 of all conditions, gliomas are made up of 29.6% of all nerve tumors listed with a predominance of oligoastrocytomas. The immunohistochemical profile is characterized by a strong positivity with the anti-IDH1antibody in case of grade II.

Research topics

  • Glioma Diagnosis and Treatment
  • Meningioma and schwannoma management
  • Neuroblastoma Research and Treatments

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.11648/j.iji.20210902.12

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.